As a specialized pharmaceutical company, Santen continues to make utmost efforts to contribute to ophthalmic treatment around the world.

Akira Kurokawa President and Chief Executive Officer Photo

To ensure sustainable growth and realize our long-term strategic vision of developing Santen into a specialized pharmaceutical company with a global presence, we are committed to the protection and improvement of eyesight and patient health. Focusing our efforts on the ophthalmic field, Santen hopes to advance treatments by delivering innovative products and services to patients and medical professionals worldwide.

To realize this long-term strategic vision, we are strengthening our development pipeline, building a global development system, and investing in the development of new businesses particularly in the rapidly growing markets of Asia and EMEA, as well as Japan, where we are maximizing our very strong position.

Globally, there are still many countries and regions where ophthalmic treatments are not sufficiently provided. There are also fields in which available treatments are not sufficiently meeting medical needs, particularly for the treatment of glaucoma and retinal disorders. I believe that Santen has a great responsibility and opportunity to address such unmet needs while meeting the expectation of all stakeholders, in particular patients and their loved ones.

Akira Kurokawa President and Chief Executive Officer